《Multiple Sclerosis And Related Disorders》雜志影響因子:2.9。
期刊Multiple Sclerosis And Related Disorders近年評價數(shù)據(jù)趨勢圖
期刊影響因子趨勢圖
以下是一些常見的影響因子查詢?nèi)肟冢?
(1)Web of Science:是查詢SCI期刊影響因子的權威平臺,收錄全球高質(zhì)量學術期刊,提供詳細的期刊引證報告,包括影響因子、分區(qū)、被引頻次等關鍵指標。
(2)?Journal Citation Reports (JCR):JCR是科睿唯安旗下的一個網(wǎng)站,提供了期刊影響因子、引用數(shù)據(jù)和相關指標。用戶可以在該網(wǎng)站上查找特定期刊的影響因子信息。
(3)中科院SCI期刊分區(qū)表:提供中科院分區(qū)的期刊數(shù)據(jù)查詢,包括影響因子和分區(qū)信息。
《Multiple Sclerosis And Related Disorders》雜志是由Elsevier出版社主辦的一本以CLINICAL NEUROLOGY為研究方向,OA非開放(Not Open Access)的國際優(yōu)秀期刊。
該雜志出版語言為English,創(chuàng)刊于2012年。自創(chuàng)刊以來,已被SCIE(科學引文索引擴展板)等國內(nèi)外知名檢索系統(tǒng)收錄。該雜志發(fā)表了高質(zhì)量的論文,重點介紹了CLINICAL NEUROLOGY在分析和實踐中的理論、研究和應用。
?學術地位:在JCR分區(qū)中位列Q2區(qū),中科院分區(qū)為醫(yī)學大類3區(qū),CLINICAL NEUROLOGY臨床神經(jīng)病學小類4區(qū)。
期刊發(fā)文分析
機構發(fā)文量統(tǒng)計
機構 | 發(fā)文量 |
UNIVERSITY OF LONDON | 55 |
TEHRAN UNIVERSITY OF MEDICAL SCIENCES | 48 |
HARVARD UNIVERSITY | 33 |
UNIVERSITY OF ALABAMA SYSTEM | 33 |
UNIVERSITY OF CALIFORNIA SYSTEM | 32 |
JOHNS HOPKINS UNIVERSITY | 30 |
UNIVERSITY OF COPENHAGEN | 29 |
UNIVERSITY OF MANITOBA | 27 |
CLEVELAND CLINIC FOUNDATION | 26 |
ISFAHAN UNIVERSITY MEDICAL SCIENCE | 26 |
國家 / 地區(qū)發(fā)文量統(tǒng)計
國家 / 地區(qū) | 發(fā)文量 |
USA | 371 |
Italy | 190 |
England | 104 |
GERMANY (FED REP GER) | 100 |
Iran | 97 |
CHINA MAINLAND | 94 |
Canada | 91 |
Australia | 67 |
Switzerland | 66 |
Spain | 60 |
期刊引用數(shù)據(jù)次數(shù)統(tǒng)計
期刊引用數(shù)據(jù) | 引用次數(shù) |
MULT SCLER J | 1163 |
NEUROLOGY | 976 |
MULT SCLER RELAT DIS | 374 |
ANN NEUROL | 326 |
J NEUROL SCI | 319 |
J NEUROL NEUROSUR PS | 270 |
J NEUROL | 262 |
BRAIN | 248 |
LANCET NEUROL | 247 |
PLOS ONE | 201 |
期刊被引用數(shù)據(jù)次數(shù)統(tǒng)計
期刊被引用數(shù)據(jù) | 引用次數(shù) |
MULT SCLER RELAT DIS | 374 |
MULT SCLER J | 67 |
FRONT NEUROL | 59 |
NEUROLOGY | 50 |
EXPERT REV NEUROTHER | 36 |
J NEUROL | 35 |
THER ADV NEUROL DISO | 34 |
J NEUROL SCI | 33 |
CURR OPIN NEUROL | 32 |
FRONT IMMUNOL | 32 |
文章引用數(shù)據(jù)次數(shù)統(tǒng)計
文章引用數(shù)據(jù) | 引用次數(shù) |
Efficacy of different rituximab therapeuti... | 53 |
MOG antibody disease: A review of MOG anti... | 39 |
Unmet needs, burden of treatment, and pati... | 22 |
Safety of cladribine tablets in the treatm... | 22 |
The disease burden of Multiple Sclerosis f... | 21 |
The validity and reliability of screening ... | 21 |
Ocrelizumab infusion experience in patient... | 18 |
Autoimmune diseases associated with Neurom... | 17 |
Effectiveness and tolerability of immunosu... | 17 |
Neuromyelitis optica spectrum disorder: Pa... | 16 |